Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

HIV-1-Gag Conserved-Element DNA Vaccine as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03560258
Recruitment Status : Active, not recruiting
First Posted : June 18, 2018
Last Update Posted : November 26, 2019
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
This study will evaluate the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who are on antiretroviral therapy (ART). The study aims to induce potent virus-specific cytotoxic T lymphocytes (CTL) responses.

Condition or disease Intervention/treatment Phase
HIV Infections Biological: p24CE1/2 pDNA vaccine Biological: p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine Biological: Full-length p55^gag pDNA vaccine Biological: Placebo Phase 1 Phase 2

Detailed Description:

This study will evaluate the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who are on antiretroviral therapy (ART).

The study will randomly assign participants to one of three groups. Participants in Arm 1 will receive p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24. Participants in Arm 2 will receive full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24. Participants in Arm 3 will receive placebo at Weeks 0, 4, 12, and 24.

Study visits will occur at Weeks 0, 4, 6, 12, 24, 26, and 48 and may include physical examinations and blood and urine collection. Some participants may undergo leukapheresis and stool sample collection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy
Actual Study Start Date : January 29, 2019
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : September 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Arm 1: p24CE1/2 pDNA + full-length p55^gag pDNA vaccine
Participants will receive p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24.
Biological: p24CE1/2 pDNA vaccine
4 mg administered by one injection/electroporation

Biological: p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine
2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55^gag pDNA administered by one injection/electroporation

Experimental: Arm 2: Full-length p55^gag pDNA vaccine
Participants will receive full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
Biological: Full-length p55^gag pDNA vaccine
4 mg full-length p55^gag pDNA vaccine administered by one injection/electroporation

Placebo Comparator: Arm 3: Placebo
Participants will receive placebo at Weeks 0, 4, 12, and 24.
Biological: Placebo
1 mL placebo administered by one injection/electroporation




Primary Outcome Measures :
  1. The number of conserved elements (CEs) with a CD4 and/or CD8 T cell response compared to baseline in an individual study participant. [ Time Frame: Measured at Week 26 ]
    A CE response (for a participant at a given timepoint) is defined by a criterion that uses Fisher's exact test to compare the proportion of peptide-stimulated CD4 and/or CD8 T cells that are cytokine positive to the proportion that are cytokine positive in the unstimulated sample (negative control), and applying a stringent p-value of 10e-5 as a cutoff. For this primary endpoint, we will sum the CD4 and CD8 responses.

  2. Occurrence of at least one greater than or equal to Grade 3 adverse event (AE) except injection site pain or tenderness of less than 48 hours duration, that is possibly, probably, or definitely related to study treatment. [ Time Frame: Measured through Week 28 ]
    Grade 4 AEs and deaths at any time on study will be considered a primary safety outcome.


Secondary Outcome Measures :
  1. The number of CEs with a CD4 T cell response compared to baseline in an individual study participant. [ Time Frame: Measured at Week 26 ]
    A CE response (for a participant at a given timepoint) is defined by a criterion that uses Fisher's exact test to compare the proportion of peptide-stimulated CD4 and/or CD8 T cells that are cytokine positive to the proportion that are cytokine positive in the unstimulated sample (negative control), and applying a stringent p-value of 10e-5 as a cutoff.

  2. The number of CEs with a CD8 T cell response compared to baseline in an individual study participant. [ Time Frame: Measured at Week 26 ]
    A CE response (for a participant at a given timepoint) is defined by a criterion that uses Fisher's exact test to compare the proportion of peptide-stimulated CD4 and/or CD8 T cells that are cytokine positive to the proportion that are cytokine positive in the unstimulated sample (negative control), and applying a stringent p-value of 10e-5 as a cutoff.

  3. The total magnitude of CD4 T cell responses against each CE added together in each study arm compared to baseline. [ Time Frame: Measured at Week 26 ]
    The change in total magnitude of CD4 T cell responses against each CE added together among study arms will be compared using the two-sided Wilcoxon rank-sum test.

  4. The total magnitude of CD8 T cell responses against each CE added together in each study arm compared to baseline. [ Time Frame: Measured at Week 26 ]
    The change in total magnitude of CD8 T cell responses against each CE added together among study arms will be compared using the two-sided Wilcoxon rank-sum test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA assay. NOTE: The term "licensed" refers to a U.S. FDA-approved kit, which is required for all IND studies. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
  • Receiving a stable ART regimen for a minimum of 2 years prior to study entry and with no changes in the components of their antiretroviral therapy for at least 90 days prior to study entry. One of the agents must include an integrase inhibitor, non-nucleoside reverse transcriptase inhibitors (NNRTI), or a boosted-protease inhibitor (PI). NOTE: Changes in the ART regimen for reasons other than virologic breakthrough during the 2-year period are acceptable.
  • CD4 cell count greater than 500 cells/mm^3 obtained within 60 days prior to study entry at any U.S. laboratory that has a CLIA certification or its equivalent.
  • Nadir CD4 cell count greater than 350 cells/mm^3. NOTE: Candidate recall or documentation is acceptable.
  • One documented plasma HIV-1 RNA that is below the limit of detection of an FDA-approved assay between 24 and 36 months prior to the screening HIV-1 RNA and/or one documented plasma HIV-1 RNA that is below the limit of detection of an FDA-approved assay between 12 and 24 months prior to the screening HIV-1 RNA, and one documented HIV-1 RNA that is below the limit of detection of an FDA-approved assay collected fewer than 12 months prior to the screening HIV-1 RNA (see the protocol).

    • NOTE: A single, unconfirmed plasma HIV-1 RNA above the limit of detection but less than 400 copies/mL is allowed if followed by an HIV-1 RNA below detectable limits, but not in the 6 months prior to screening.
    • NOTE: One documented plasma HIV-1 RNA that is below the limit of detection between 24 and 36 months prior to the screening HIV-1 RNA and one between 12 and 24 months prior to the screening HIV-1 RNA are preferred. However, in cases where a plasma HIV-1 RNA is not available in one of these windows, but there has been uninterrupted ART during the window and suppressed HIV-1 RNA before and after the window, the participant may be enrolled.
  • Plasma HIV-1 RNA level that is below the limit of detection of an FDA-approved assay within 60 days prior to study entry.
  • The following laboratory values obtained within 60 days prior to entry by any U.S. laboratory that has a CLIA certification or its equivalent:

    • Absolute neutrophil count (ANC) greater than or equal to 750 cells/mm^3
    • Hemoglobin greater than or equal to 10.0 g/dL for men and greater than or equal to 9.0 g/dL for women
    • Platelet count greater than or equal to 100,000/mm^3
    • Prothrombin time (PT), partial thromboplastin time (PTT), and INR less than 1.5 x upper limit of normal (ULN)
    • Creatinine clearance greater than or equal to 50 mL/min estimated by the Cockcroft-Gault equation. NOTE: A program for calculating creatinine clearance by the Cockcroft-Gault method is available on www.fstrf.org.
    • Alanine aminotransferase (ALT) (SGPT) less than or equal to 2.5 x ULN
    • Total bilirubin less than 1.6 x ULN (if on atazanavir less than or equal to 5 x ULN)
  • HCV antibody negative result within 60 days prior to study entry or, if the HCV antibody result is positive, a negative HCV RNA result prior to study entry.
  • Negative HBsAg result obtained within 60 days prior to study entry.
  • Men and women age greater than or equal to 18 to less than or equal to 65 years
  • Documentation of the availability of the stored pre-entry peripheral blood mononuclear cell (PBMC) specimens for T cell assays. Sites must receive confirmation from the processing lab via phone, e-mail, or fax that specimens have been entered into the ACTG Laboratory Data Management System (LDMS).
  • Ability and willingness of participant or legal guardian/representative to provide informed consent
  • Ability and willingness of participant to continue cART throughout the study.
  • For females of reproductive potential, negative serum or urine pregnancy test within 15 days prior to entry by any clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC)/CLIA-waived test. NOTE: Reproductive potential is defined as girls who have reached menarche and women who have not been post-menopausal for at least 12 consecutive months with follicle-stimulating hormone (FSH) greater than or equal to 40 IU/mL or 24 consecutive months if an FSH is not available, or have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy).
  • If participating in sexual activity that could lead to pregnancy, willingness of female participants to use two forms of effective contraception while receiving study medication and for 3 months after stopping study medication is required.

    • NOTE A: Effective forms of contraception include:
    • Barrier methods (condoms [male or female] with or without a spermicidal agent, diaphragm, or cervical cap [with spermicide])
    • Hormone-based contraception (oral, patch, parenteral, implants, or vaginal ring)
    • Intrauterine device (IUD)
    • NOTE B: If the female participant is not of reproductive potential (women who are post-menopausal as defined above, or women who have undergone surgical sterilization [e.g., hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy]), she is eligible without requiring the use of a contraceptive method. Acceptable documentation of surgical sterilization and menopause is participant-reported history.
  • Indication of willingness to have the leukapheresis procedure. NOTE: Until 60 days after the last participating site is activated, each site will be limited to three participants in screening/enrollment at any given time. During this time period, these first three participants at each site will be required to agree at the screening visit to undergo the leukaphereses at the pre-entry and week 26 timepoints. Once the 60 day period after the last participating site is activated has passed, and at least 50% of the target accrual has agreed to undergo the leukaphereses, a study participant agreeing to the leukaphereses will be optional but highly recommended. The study team will inform the participating sites when this leukapheresis-optional period has begun.

Exclusion Criteria:

  • History of malignancy within the last 5 years prior to study entry or current malignancy requiring cytotoxic therapy. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
  • History of HIV-related opportunistic infections within the last 5 years prior to study entry. NOTE: The CDC classifications are available on the A5369 protocol-specific webpage (PSWP).
  • History of or active autoimmune disorders including but not limited to inflammatory bowel diseases, scleroderma, severe psoriasis, myocarditis, uveitis, pneumonitis, systemic lupus erythematosus, rheumatoid arthritis, optic neuritis, myasthenia gravis, adrenal insufficiency, autoimmune thyroiditis, or sarcoidosis. NOTE: For questions related to the definition of autoimmune disorders, sites should contact the A5369 core team per the Study Management section.
  • Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate IM injection.
  • A skin-fold measurement of the cutaneous and subcutaneous tissue for eligible injection sites (on the medial deltoid or vastus lateralis muscles) that exceeds 50 mm. NOTE: The skin-fold measurement must be conducted in accordance with the procedure described in the TDS-IM Instructions for Use (see A5369 MOPS).
  • Use of any prior HIV vaccine (prophylactic and/or therapeutic) within 1 year prior to study entry. NOTE: A documented study placebo recipient may participate.
  • Use of any investigational treatment within 6 months prior to study entry.
  • Any licensed or experimental non-HIV vaccination (e.g., hepatitis B, influenza, pneumococcal polysaccharide) within 4 weeks prior to study entry. NOTE: Participants with anticipated need to receive non-HIV vaccinations within 2 weeks prior to the scheduled study vaccination #2 (week 4), or #3 (week 12), or #4 (week 24) injection should be excluded.
  • Use of any infusion blood product or immune globulin within 3 months prior to study entry.
  • Acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and/or hospitalization within 30 days prior to entry.
  • Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), systemic cytotoxic chemotherapy, or investigational therapy within 60 days prior to study entry. NOTE: Participants receiving stable physiologic glucocorticoid doses, defined as prednisone less than or equal to 10 mg/day or the equivalent, will not be excluded. Stable physiologic glucocorticoid doses should not be discontinued for the duration of the study. In addition, participants receiving inhaled or topical corticosteroids will not be excluded.
  • Intent to use immunomodulators (e.g., IL-2, IL-12, interferons, or TNF modifiers) during the course of the study.
  • Known or suspected hypersensitivity to any vaccine component, including hypersensitivity to amide-type local anesthetics, such as lidocaine (Xylocaine), mepivacaine (Polocaine/Carbocaine), etidocaine (Duranest), bupivacaine (Marcaine), or prilocaine.
  • Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.
  • History of cardiac arrhythmia or palpitations (e.g., supraventricular tachycardia, atrial fibrillation, frequent ectopy, or sinus bradycardia [i.e., less than 50 beats per minute on exam]) prior to study entry. NOTE: Sinus arrhythmia is not excluded.
  • History of syncope or fainting episode within 1 year of study entry.
  • Seizure disorder or any history of prior seizure.
  • Extensive tattoos covering the site of administration (upper left and right medial deltoid muscles and left and right vastus lateralis muscles).
  • Presence of any surgical or traumatic metal implants at the site of administration (medial deltoid or vastus lateralis muscles).
  • Immune deficiency other than HIV.
  • Breastfeeding or pregnancy.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Current HCV antiviral therapy.
  • Type I or type II diabetes mellitus.
  • Weight less than 50 kg or greater than 200 kg.
  • Known to have been started on antiretroviral therapy within 3 months of the presumed or known date of first acquiring HIV-1 infection; i.e., treated during acute HIV-1 infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03560258


Locations
Layout table for location information
United States, Alabama
Alabama CRS
Birmingham, Alabama, United States, 35294
United States, California
UCLA CARE Center CRS
Los Angeles, California, United States, 90035
Ucsf Hiv/Aids Crs
San Francisco, California, United States, 94110
United States, Illinois
Northwestern University CRS
Chicago, Illinois, United States, 60611
Rush University CRS
Chicago, Illinois, United States, 60612
United States, Massachusetts
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
Boston, Massachusetts, United States, 02115
United States, New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS
Rochester, New York, United States, 14642
United States, North Carolina
Chapel Hill CRS
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Ohio State University CRS
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Penn Therapeutics, CRS
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, United States, 37204
United States, Washington
University of Washington AIDS CRS
Seattle, Washington, United States, 98104-9929
Puerto Rico
Puerto Rico AIDS Clinical Trials Unit CRS
San Juan, Puerto Rico, 00935
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Study Chair: Jeffrey M. Jacobson, MD Lewis Katz School of Medicine at Temple University
  Study Documents (Full-Text)

Documents provided by National Institute of Allergy and Infectious Diseases (NIAID):
Informed Consent Form  [PDF] March 9, 2018

Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT03560258    
Other Study ID Numbers: ACTG A5369
38398 ( Registry Identifier: DAIDS-ES Registry Number )
First Posted: June 18, 2018    Key Record Dates
Last Update Posted: November 26, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie results in the publication, after deidentification.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
Access Criteria:
  • With whom?

    • Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
  • For what types of analyses?

    • To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
  • By what mechanism will data be made available?

    • Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data."

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs